Compare Recursion Pharmaceuticals Inc (RXRX) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SAP SE — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while SAP SE trades at $214.78 (market cap $238.67B). The key difference: SAP SE is far larger — about 111.5× Recursion Pharmaceuticals Inc's market cap, and SAP SE pays a 1.38% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and SAP SE for 118 Days on average.
| RXRX | SAP | |
|---|---|---|
Market Cap | $2.14B | $238.67B |
Volume | 30,789,535 | 2,252,662 |
Sector | Health | Technology |
52-Week High | $6.79 | $280.46 |
52-Week Low | $2.84 | $146.38 |
Typical Hold Time | 23 Days | 118 Days |
Enterprise Value | $1.66B | $237.42B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
SAP trades at $212.40, up 1.08% today, with a bullish technical signal from moving averages and strong support at $208. The company reported robust 2025 results with revenue of $36.80B and net income of $7.16B, though Q2 2026 EPS missed expectations. Analyst consensus is a Buy with a $253.40 price target, reflecting optimism in cloud and AI initiatives.
Outlook remains positive driven by cloud revenue growth and AI integration, but risks include competitive pressures and execution challenges. The stock offers upside to consensus targets if margin expansion and deal momentum continue, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
